Trial Profile
Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Colorectal cancer vaccine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2012 Actual end date (Dec 2011) added as reported by University Hospital Medical Information Network - Japan record.
- 09 Jun 2012 Status changed from suspended to completed as reported by University Hospital Medical Information Network - Japan record.
- 09 Dec 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan record.